Summit Therapeutics plc Summit Appoints Dr David Roblin As Chief Operating Officer And President Of Research & Development
18 January 2017 - 11:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit', 'Company' or the 'Group')
SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF OPERATING OFFICER AND PRESIDENT
OF RESEARCH & DEVELOPMENT
Oxford, UK, 18 January 2017 - Summit Therapeutics plc (AIM: SUMM,
NASDAQ: SMMT), the drug discovery and development company advancing
therapies for Duchenne muscular dystrophy ('DMD') and C. difficile
infection ('CDI'), today announces the appointment of Dr David Roblin as
Chief Operating Officer ('COO') and President of Research and
Development. In this new non-board role at Summit, Dr Roblin will lead
R&D and Commercial functions to support the development of the DMD and
CDI programmes. Dr Roblin, who has been acting as a research and
development adviser to Summit since 2014, will take up his new role on
an interim basis in April 2017 with this becoming full-time in June
2017.
Dr Roblin has had a highly successful career in the life sciences
industry, including senior leadership roles at Pfizer and Bayer, which
involved overseeing the research, development and commercial launch of
drugs across several therapy areas including infectious diseases. Dr
Roblin's most recent role was COO and Director of Scientific Translation
at the Francis Crick Institute, a London-based biomedical institute
dedicated to understanding the fundamental biology underlying health and
disease.
Mr Glyn Edwards, Chief Executive Officer of Summit said: "David has had
a distinguished career in the biopharmaceutical industry with over 25
years of experience, and we are delighted he is committing himself to
Summit as COO and President of R&D. David will be instrumental to Summit
as we continue to advance our two important medicines in DMD and CDI
through late-stage clinical trials."
"Summit has two strong scientific programmes with the potential to
significantly advance the current standard of care in their respective
disease areas. In CDI, the positive results from Summit's Phase 2 proof
of concept trial highlight ridinilazole's impressive translational
medicine story, and in DMD, we are nearing the first data from our Phase
2 trial of ezutromid evaluating the mechanism for utrophin modulation,"
said Dr David Roblin. "As we continue to advance both programmes in the
clinic, I look forward to working with the team with the goal of
delivering success for patients and their families, and our
shareholders."
About Dr David Roblin MBBS, BSc, FRCP, FFPM
Dr David Roblin has had an extensive and highly successful career in the
life sciences industry. Dr Roblin held senior leadership roles at Pfizer
and Bayer where he was involved in research, development and
commercialisation. At Pfizer, he was Head of Research, Site Director and
CMO for Europe R&D and he and his units were responsible for the
development of several important and successful medicines. At Bayer, he
was Head of Therapy Area for Anti-infectives where he was involved in
the successful development of a number of antibiotics, including
Avelox(TM) and Cipro(TM). In 2014 Dr Roblin was appointed COO and
Director of Scientific Translation at the Francis Crick Institute in
London where he led on establishing the operations of a new biomedical
research institute at a purpose built state-of-the-art research facility
in central London. On stepping down from his full-time roles, Dr Roblin
will become a Senior Scientific Translation Fellow and Chair of the
Translation Advisory Group at the Francis Crick Institute.
Dr Roblin has been Chief Medical Officer and a Non-Executive Director to
a number of biotech companies. He also serves on the Major Awards
Committee of the Biomedical Catalyst Fund and of the Confidence in
Concept and Proximity to Discovery of Medical Research Council. He also
serves on the LEO Foundation Prize Committee.
Dr Roblin has a degree in biochemistry from University College London
and later qualified in medicine from St George's Hospital. He is a
Fellow of the Royal College of Physicians and a Fellow of the Faculty of
Pharmaceutical Medicine. He is an honorary Professor of Medicine at
Swansea University and Professor of Translational Medicine at St
George's. He is a Board Director of MedCity and Destiny Pharma. Before
entering the life sciences industry, Dr Roblin practised medicine for
five years.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialization of novel medicines for indications for
which there are no existing or only inadequate therapies. Summit is
conducting clinical programs focused on the genetic disease Duchenne
muscular dystrophy and the infectious disease C. difficile infection.
Further information is available at www.summitplc.com and Summit can be
followed on Twitter (@summitplc https://twitter.com/Summitplc ).
For more information, please contact:
Summit Therapeutics
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer
(Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Lauren Kettle
MacDougall Biomedical Communications
(US media contact) Tel: +1 781 235 3060
Chris Erdman / Karen Sharma cerdman@macbiocom.com ksharma@macbiocom.com
Consilium Strategic Communications
(Financial public relations, UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / summit@consilium-comms.com
Jessica Hodgson / Lindsey Neville
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about development and
potential commercialisation of our product candidates, the therapeutic
potential of our product candidates, the timing of initiation,
completion and availability of data from clinical trials, the potential
benefits and future operation of the collaboration with Sarepta
Therapeutics Inc., including any potential future payments thereunder,
any other potential third-party collaborations and expectations
regarding the sufficiency of our cash balance to fund operating expenses
and capital expenditures, and other statements containing the words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project," "should,"
"target," "would," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation of future clinical trials, availability and timing of data
from ongoing and future clinical trials and the results of such trials,
whether preliminary results from a clinical trial will be predictive of
the final results of that trial or whether results of early clinical
trials will be indicative of the results of later clinical trials,
expectations for regulatory approvals, availability of funding
sufficient for our foreseeable and unforeseeable operating expenses and
capital expenditure requirements and other factors discussed in the
"Risk Factors" section of filings that we make with the Securities and
Exchange Commission, including our Annual Report on Form 20-F for the
fiscal year ended 31 January 2016. In addition, any forward-looking
statements included in this press release represent our views only as of
the date of this release and should not be relied upon as representing
our views as of any subsequent date. We specifically disclaim any
obligation to update any forward-looking statements included in this
press release.
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
January 18, 2017 07:00 ET (12:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024